-+ 0.00%
-+ 0.00%
-+ 0.00%

LILLY'S TRIPLE AGONIST, RETATRUTIDE, SUCCESSFUL IN TWO ADDITIONAL PHASE 3 OBESITY TRIALS, DELIVERING SIGNIFICANT IMPROVEMENTS IN WEIGHT AND A1C

Reuters·07/23/2026 10:45:00

Please log in to view news